CI

At a glance

ClinicalIndex Comparison Record
Phase 4Terminated· 2 enrolled
Drug / intervention
Sodium Glycididazoledrug
Likely dose
Sodium Glycididazole 800mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02721550
NCT02721550Phase 4Terminated
Terminated
CompareCT.gov

A Perspective Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma

Shandong Cancer Hospital and Institute·interventional·Posted Mar 29, 2016·Updated Oct 11, 2019

In Brief

A Phase 4 clinical trial evaluating Sodium Glycididazole for Esophageal Neoplasms. Terminated early, enrolled 2 participants across 9 sites.

Signals

Trial was terminated early

Detailed Summary

This is a perspective, multicenter,single arm, open label study to evaluate the efficacy and safety of treatment with CMNa combined with preoperatie concurrent chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma . Analyses of primary objective (pathologic Complete Response) will be done as defined in the protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Neoplasms
CountriesChina
Collaborators--

Timeline

Phase 4TerminatedFinished
20162017201820192020202120222023202420252026
First PostedMar 29, 2016
Enrollment StartAug 1, 2016
Primary CompletionJun 30, 2018
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 10.3 years ago

Interventions

Sodium Glycididazoledrug

800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.